secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-073377
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom reports Q4 revenue $57.6M, FY2025 revenue $175.1M (+217% YoY); expects operating profitability in Q3 2026
--------------------------------------------------------------------------------

- Q4 net revenues $57.6M; FY2025 net revenues $175.1M, a 217% increase over FY2024.
- Q4 GAAP net loss narrowed to $21.1M from $74.5M in Q4 2024.
- Non-GAAP adjusted net loss for Q4 was $5.7M, improved from $56.4M in Q4 2024.
- Expects operating profitability beginning Q3 2026 and for FY2026; cash flow positivity in 2027.
- Completed $130M equity offering Jan 2026; modified term loan to $175M principal, extended maturity to Feb 2029; pro forma cash ~$190M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312526073377/0001193125-26-073377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312526073377/d119012d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-073377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer